CLOs on the Move


 
Founded in 2012 by inventor and serial entrepreneur Clay Alexander, Ember has developed and patented a disruptive new technology that will change the way the world eats and drinks. We are an incredible team of world-class product designers and engineers formerly with Apple, Google, Nokia, Microsoft, and Amazon Labs, with big plans to transform the drinkware and dishware industry.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ember.com
  • 4607 Lakeview Canyon Rd. Ste. 500
    Westlake Village, CA USA 91361
  • Phone: 805.870.5658

Executives

Name Title Contact Details
Melissa Miller
Senior Vice President and General Counsel Profile

Similar Companies

HexaTech

HexaTech is a Morrisville, NC-based company in the Computers and Electronics sector.

netMercury

netMercury is a Dallas, TX-based company in the Computers and Electronics sector.

Whizz Systems

Whizz Systems Incorporated is a Santa Clara, CA-based company in the Computers and Electronics sector.

Maxim Integrated

At Maxim, we invent highly integrated solutions that make technology seamless. We channel our collective expertise to stretch the limits of technology, understand your needs, and help you get to market faster.

Xceleron

Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them.  We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.